We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test Developed for Parkinson’s Disease

By LabMedica International staff writers
Posted on 12 May 2016
Currently no clinical biomarker test exists for Parkinson's and the only means of diagnosis is a neurological examination and by the time patients develop symptoms and undergo the examination, large numbers of vital brain cells have already been destroyed.

An estimated 80,000 Australians and more than 6.3 million people worldwide are affected by Parkinson's, which can severely impair mobility and quality of life. More...
Diseases such as Parkinson's and Alzheimer's have long been believed to involve malfunction of cell mitochondria, which are the cells' energy factories.

Scientists at the La Trobe University (Melbourne, Australia) have developed blood test that will enable doctors to detect with unprecedented reliability the abnormal metabolism of blood cells in people with Parkinson's, which will allow them to provide treatment options much earlier. The blood test has been trialed on a small test group of 38 people (29 with Parkinson's and a control group of nine) with great reliability. When the next stage of testing is complete, the sample will total about 100 people: 70 with Parkinson's and a control group of 30.

About a decade ago, the team discovered that a permanently switched on 'alarm' at the cellular level could be responsible for symptoms in many incurable conditions involving defective mitochondria. This led to an important new understanding of how mitochondrial defects damage cells, namely that it is a signaling disorder, rather than a fundamental energy insufficiency as previously thought. The scientists demonstrated for the first time, using a laboratory organism called Dictyostelium, that an energy- and stress-sensing protein, known as 5' adenosine monophosphate-activated protein kinase (AMPK), was permanently activated in mitochondrially diseased cells. When energy production was compromised, this protein began signaling and interfering with other signaling pathways, causing cell functions to shut down.

Paul Robert Fisher, PhD, a professor of Microbiology who led the study, said, “This is a really exciting discovery. Parkinson's is a debilitating disorder and currently there is no cure. However, early diagnosis and treatment could enable better outcomes and a greater quality of life for people with the condition, which will be of great benefit to sufferers and their families. In people with Parkinson's, something causes their cells to become 'hyperactive', which in turn increases the production of toxic oxygen by-products and over time damages vital cells in the brain.”

Related Links:
La Trobe University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Blood Gas and Chemistry Analysis System
Edan i500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.